DFTX-201
Inflammatory Bowel Disease (IBD)
PreclinicalLead Optimization
Key Facts
Indication
Inflammatory Bowel Disease (IBD)
Phase
Preclinical
Status
Lead Optimization
Company
About Definium Therapeutics
Definium Therapeutics is a public biotech company dedicated to translating innovative science into transformative medicines for patients with cancer and immune disorders. Its core strategy involves targeting key disease-driving pathways that have eluded conventional drug discovery approaches. The company's lead asset is in Phase 1/2 development, supported by a robust preclinical pipeline and a strong intellectual property portfolio. Definium aims to establish itself as a leader in precision oncology and immunology through strategic clinical execution and potential partnerships.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease (IBD) Drugs
| Drug | Company | Phase |
|---|---|---|
| COSMO-232 | Cosmo Pharmaceuticals | Preclinical |
| Tamuzimod | Ventyx Biosciences | Phase 2 |
| VTX958 | Ventyx Biosciences | Phase 2 |
| GPR35 Agonist | Nxera Pharma | Preclinical |
| SL-325 | Shattuck Labs | Phase 2 |
| SL-425 | Shattuck Labs | Phase 1 |
| ABS-101 | AbSci | Pre-clinical |
| Metabolite Delivery Platform (Therapeutic Programs) | ClostraBio | Pre-clinical |
| ABO21009 | AboleIIs Pharma | Phase 1 |